Recombinant Human Insulin-like growth factor-binding protein 5 protein (IGFBP5) (Active)

In Stock
Code CSB-AP002501HU
Size $142
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

>96% as determined by SDS-PAGE.
Less than 1.0 EU/μg as determined by LAL method.
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4 μg/ml, corresponding to a specific activity of >2500 IU/mg in the presence of 15 ng/ml of rHuIGF-II.
Target Names
Uniprot No.
Research Area
Alternative Names
IBP 5; IBP-5; IBP5; IBP5_HUMAN; IGF binding protein 5; IGF BP5; IGF-binding protein 5; IGFBP 5; IGFBP-5; IGFBP5; Insulin like growth factor binding protein 5; Insulin-like growth factor-binding protein 5
Homo sapiens (Human)
Expression Region
Complete Sequence
Mol. Weight
28.6 kDa
Protein Length
Full Length of Mature Protein
Tag Info
Lyophilized powder
Lyophilized from a 0.2 µm filtered PBS, pH 7.0
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
5-10 business days
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Gene References into Functions
  1. Data suggest that IGFBP5 nuclear import is mediated by KPNA5/KPNB1 complex; nuclear localization sequence of IGFBP5 is critical domain in this nuclear translocation. (IGFBP5 = insulin-like growth factor binding protein-5; KPNA5 = karyopherin subunit alpha-5; KPNB1 = karyopherin subunit beta-1/importin-beta) PMID: 28835592
  2. These results suggest that the C-terminus of IGFBP-5 exerts anti-cancer activity by inhibiting angiogenesis via regulation of the Akt/ERK and NF-kB-VEGF/MMP-9 signaling pathway. PMID: 28008951
  3. AMP-IBP5 markedly enhanced keratinocyte migration and proliferation. AMP-IBP5-induced keratinocyte activation was mediated by Mrg X1-X4 receptors with MAPK and NF-kappaB pathways. PMID: 28554590
  4. Factor Xa induced endothelial cell senescence through IGFBP-5. PMID: 27752126
  5. The findings suggest that miR-140 suppresses colorectal cancer progression and metastasis, possibly through downregulating ADAMTS5 and IGFBP5. PMID: 27906093
  6. MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling. PMID: 29016699
  7. dysregulation of DNMT3A and IGFBP5 is relevant to preeclampsia. Thus, we propose that DNMT3A and IGFBP5 can serve as potential markers and targets for the clinical diagnosis and therapy of preeclampsia. PMID: 28049695
  8. IGFBP5 promoter and exon-I methylation did not have any differences between tumor and adjacent tissues so that IGFBP5 methylation did not change IGFBP5 gene regulation in breast cancer. PMID: 27612043
  9. IGFBP5 promoted osteogenic differentiation potentials of periodontal ligament stem cells and Wharton's jelly umbilical cord stem cells via the JNK and MEK/Erk signalling pathways. PMID: 27484838
  10. Data demonstrate that dysregulation of miR-143-3p:Igfbp5 interactions in satellite cells with age may be responsible for age-related changes in satellite cell function. PMID: 26762731
  11. Results shed light on the mechanism of IGFBP5 as a potential tumor-suppressor in melanoma progression. PMID: 26010068
  12. data provide further insights into the role of cellular compartmentalization in IGFBP-5-induced fibrosis PMID: 26103640
  13. Demethylation of IGFBP5 by Histone Demethylase KDM6B Promotes Mesenchymal Stem Cell-Mediated Periodontal Tissue Regeneration by Enhancing Osteogenic Differentiation and Anti-Inflammation Potentials. PMID: 25827480
  14. rs4442975 at 2q35 flanks a transcriptional enhancer that physically interacts with the promoter of IGFBP5. Evidence suggests that the g-allele confers increased breast cancer susceptibility through relative downregulation of IGFBP5. PMID: 25248036
  15. IGFBP5 mRNA expression is a good indicator in clinical outcome of breast cancer patients. PMID: 25422220
  16. miR-204-5p suppresses IGFBP5 expression by direct binding to the 3' untranslated region. PMID: 25603050
  17. IGFBP-5 may be a negative modulator of RASSF1C/ PIWIL1 growth-promoting activities. PMID: 25007054
  18. IGFBP-5 induces its pro-fibrotic effects, at least in part, via DOK5. IGFBP-5 and DOK5 are both increased in systemic sclerosis fibroblasts and tissues and may thus be acting in concert to promote fibrosis. PMID: 24551065
  19. IGFBP-5 is important in maintaining epithelial-mesenchymal boundaries and thus may limit metastasis and fibrosis by inducing an orderly repair mechanism, very distinct from the fibrotic disruption induced by TGFbeta1. PMID: 24120850
  20. Serum IGFBP-5 concentrations were lower in Crohn's disease patients compared to healthy controls regardless of disease activity or the presence of stricture formation. PMID: 24379630
  21. IGFBP-5 modulates the efficiency of estrogen-triggered activation of the Akt/PKB signaling pathway which has been associated with growth factor/ ERalpha cross-talks. PMID: 23499909
  22. IGFBP-5 overexpression is a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. PMID: 23539739
  23. IGFBP5 domains modulate tumorigenicity and metastasis of human osteosarcoma in different ways PMID: 23665505
  24. Data suggest that insulin-like growth factor-binding protein 5 (IGFBP5) regulation by calcium-dependent chloride channel DOG1. PMID: 23576565
  25. The IGFBP5 enhanced adhesion, it inhibited cell migration, although this was not evident using the truncated C-terminal mutant, suggesting that effects of IGFBP5 on adhesion and migration involve different mechanisms. PMID: 22328518
  26. c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling PMID: 22252554
  27. This study demonistrated that IGFBP5 was significantly decreased in skeletal muscel in patient with amyotrophic lateral sclerosis. PMID: 22246875
  28. Data revealed a strong induction of several genes encoding components of the extracellular matrix, such as collagens, COMP, IGFBP5 and biglycan. PMID: 21029365
  29. Insulin-like growth factor binding protein 5 is a novel marker that has an important role in the pathogenesis of osteosarcoma. The loss of insulin-like growth factor binding protein 5 function may contribute to metastasis in osteosarcoma. PMID: 21460855
  30. The IGFBP5 polymorphism is functional and may potentially be a biomarker for susceptibility to late-stage risk of squamous cell carcinoma of the head and neck. PMID: 20949447
  31. results suggest that PGE(2) may play an important role in controlling cellular senescence of HDFs through the regulation of IGFBP5 and therefore may contribute to inflammatory disorders associated with aging PMID: 21191810
  32. Decreased Cav-1 expression in fibrotic diseases likely leads to increased deposition of IGFBP-5 in the extracellular matrix. PMID: 20345844
  33. the L-domain of IGFBP-5 is a novel TNFR1 ligand that functions as a competitive TNF-alpha inhibitor. PMID: 21256825
  34. IGFBP-5 has an effect on human hair shape. PMID: 20944648
  35. Data indicate that retinal astrocytes enhance the proliferation of cone-like retinoblastoma cells by deploying IGFBP5, a factor that also provides trophic support to the tumor cells' non-neoplastic counterparts. PMID: 20508032
  36. Data show that IGFBP5 expression is down-regulated during 4HPR-induced neuronal differentiation of human RPE cells through a MAPK signal transduction pathway involving C/EBPbeta. PMID: 20583135
  37. insulin-like growth factor binding protein 5 is a modulator of tamoxifen resistance in breast cancer PMID: 20354179
  38. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. PMID: 19948051
  39. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). PMID: 11821401
  40. role in stimulating growth and IGF-I secretion in intestinal smooth muscle by ras-dependent activation of MAP kinase signaling pathways PMID: 11923300
  41. c-Myb and B-Myb transactivate the IGFBP-5 promoter through binding-dependent and -independent mechanisms. PMID: 11973331
  42. cDNA probes were used to analyze the gene expression of IGFBP-5 in luteinized granulosa cells from different-sized follicles after ovarian hyperstimulation. Transcript levels increased with increasing follicular fluid (FF) volume PMID: 12005306
  43. IGFBP-5 is a potent growth inhibitor and proapoptotic agent in human breast cancer cells via modulation of cell cycle regulation and apoptotic mediators PMID: 12777377
  44. Fibronectin and IGFBP-5 bind to each other, and this binding negatively regulates the ligand-dependent action of IGFBP-5 by triggering IGFBP-5 proteolysis. PMID: 14645245
  45. The IGFBP-5 C-domain is necessary and sufficient for its nuclear localization, and residues K206, K208, K217, and K218 are particularly critical. The IGFBP-5 N-domain contains a putative transactivation domain. PMID: 15001525
  46. exogenous IGFBP-5 increases apoptosis by binding to and inhibiting the activities of insulin-like growth factors PMID: 15155755
  47. Understanding the mechanism of how cleavage of IGFBP-5 by this protease (IGFBPase) alters its activity will help to further our understanding of the biologic actions of the IGFs PMID: 15534875
  48. Inhibition of expression of IGFBP-5 by micro and small interfering RNA has marked effect on neuroblastoma cell proliferation, apoptosis, and differentiation PMID: 15618969
  49. IGFBP-5 has a role in growth and differentiation of neuroblastoma cells PMID: 15650232
  50. Activation by C/EBP alpha and beta did not depend on their binding to the C/EBP site, since they still activated IGFBP-5 promoter. PMID: 15777798

Show More

Hide All

Subcellular Location
Tissue Specificity
Osteosarcoma, and at lower levels in liver, kidney and brain.
Database Links

HGNC: 5474

OMIM: 146734

KEGG: hsa:3488

STRING: 9606.ENSP00000233813

UniGene: Hs.607212

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To